3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
34
Melanoma
13
Carcinoma, Hepatocellular
13
Neoplasm Metastasis
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Neoplasms
9
Esophageal Neoplasms
9
Colorectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
5
Breast Neoplasms
5
Recurrence
4
Rectal Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Head and Neck Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroblastoma
2
Interventions
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
4
napabucasin
3
Paclitaxel
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
entinostat
2
anlotinib
2
Taxes
2
Sunitinib
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Carboplatin
2
sipuleucel-T
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
ixabepilone
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Glandular and Epithelial
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled